In last trading session, Immix Biopharma Inc (NASDAQ:IMMX) saw 0.37 million shares changing hands with its beta currently measuring 0.21. Company’s recent per share price level of $2.20 trading at $0.23 or 11.62% at ring of the bell on the day assigns it a market valuation of $60.49M. That closing price of IMMX’s stock is at a discount of -252.27% from its 52-week high price of $7.75 and is indicating a premium of 42.73% from its 52-week low price of $1.26. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.26 million shares which gives us an average trading volume of 136.14K if we extend that period to 3-months.
For Immix Biopharma Inc (IMMX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.14 in the current quarter.
Immix Biopharma Inc (NASDAQ:IMMX) trade information
Upright in the green during last session for gaining 11.62%, in the last five days IMMX remained trading in the green while hitting it’s week-highest on Friday, 11/29/24 when the stock touched $2.20 price level, adding 4.35% to its value on the day. Immix Biopharma Inc’s shares saw a change of -68.22% in year-to-date performance and have moved 30.89% in past 5-day. Immix Biopharma Inc (NASDAQ:IMMX) showed a performance of 33.27% in past 30-days. Number of shares sold short was 0.43 million shares which calculate 2.94 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a rise of 68.57% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 7. It follows that stock’s current price would drop -218.18% in reaching the projected high whereas dropping to the targeted low would mean a loss of -218.18% for stock’s current value.
Immix Biopharma Inc (IMMX) estimates and forecasts
Statistics highlight that Immix Biopharma Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 4.21% of value to its shares in past 6 months, showing an annual growth rate of 28.09% while that of industry is 17.70. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -63.30% during past 5 years.
Immix Biopharma Inc (NASDAQ:IMMX)’s Major holders
Insiders are in possession of 40.10% of company’s total shares while institution are holding 17.64 percent of that, with stock having share float percentage of 29.45%. Investors also watch the number of corporate investors in a company very closely, which is 17.64% institutions for Immix Biopharma Inc that are currently holding shares of the company. AIGH CAPITAL MANAGEMENT LLC is the top institutional holder at IMMX for having 1.41 million shares of worth $2.79 million. And as of 2024-06-30, it was holding 6.0017 of the company’s outstanding shares.
The second largest institutional holder is BLEICHROEDER LP, which was holding about 0.85 million shares on 2024-06-30. The number of shares represents firm’s hold over 3.6266 of outstanding shares, having a total worth of $1.68 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 30, 2024 , the former fund manager was holding 399.29 shares of worth $0.84 million or 1.45% of the total outstanding shares. The later fund manager was in possession of 199.25 shares on Jun 30, 2024 , making its stake of worth around $0.42 million in the company or a holder of 0.72% of company’s stock.
